A paradigm shift in myelodysplastic syndromes

Leukemia

Volumn 10, Issue 10, 1996, Pages 1648-1652

  Raza, A ^a,c   Mundle, S ^a   Shetty, V ^a   Alvi, S ^a   Chopra, H ^a   Span, L ^a   Parcharidou, A ^b   Dar, S ^a   Venugopal, P ^a   Borok, R ^c   Gezer, S ^a   Showel, J ^a   Loew, J ^c   Robin, E ^d   Rifkin, S ^e   Alston, D ^f   Hernandez, B ^f   Shah, R ^g   Kaizer, H ^a   Gregory, S ^a   Preisler, H ^a   more..

^a RUSH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Ingalls Memorial Hospital   (United States)

^e NORTHWEST COMMUNITY HOSPITAL   (United States)

^f LaPorte Cancer Treatment Center   (United States)

^g Lake Forest Hospital   (United States)

Author keywords

Apoptosis; Interleukin 1 (lL 1 ); Myelodysplastic syndromes (MDS); Transforming growth factor beta (TGF ); Tumor necrosis factor alpha (TNF )

Indexed keywords

CD34 ANTIGEN; INTERLEUKIN 1BETA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PRIORITY JOURNAL;

EID: 10144248960     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Bennett JM, Catovsky D, Flandrin DMT, Galton GDAG, Gralnick HR, Sultan C. Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
2. Resegotti L. The nature and natural history of myelodysplasia. Haematologica 1993; 5: 191-204.
3. Verhoef GEG, Pittaluga S, Wolf-Peeters CDe, Boogaerts MA. FAB classification of myelodysplastic syndromes: merits and controversies. Ann Hematol 1995; 71: 3-11.
4. Weimar IS, Bourhis J-H, Gast GCD, Gerristen WR. Clonality in myelodysplastic syndromes. Leuk Lymphoma 1993; 13: 215-221.
5. Raskind WH, Tirumali N, Jacobson R, Singer J, Fialkow PJ. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 1984; 63: 1318-1323.
6. Preisler HD, Early A, Raza A, Vlahides G, Marinello MJ, Browman C, Vlahides G, Marinello MJ, Stein AM. Therapy of secondary acute non-lymphocytic leukemia with cytarabine. New Engl J Med 1983; 308: 21-23.
7. Raza A, Preisler HD, Li YQ, Larson R, Goldberg J, Browman G, Bennett J, Grunwald H, Vogler R, Kukla C. Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia. Am J Hematol 1993; 42: 359-366.
8. Barton JC, Conrad ME, Parmley RT. Acute lymphoblastic leukemia in idiopathic refractory sideroblastic anemia: evidence for a common lymphoid and myeloid progenitor cell. Am J Hematol 1980; 9: 109-115.
9. Nagler A, Brenner B, Tatarsky I. Secondary refractory anemia with excess of blasts in transformation terminating as acute lymphoblastic leukemia. Acta Hematol 1986; 76: 164-165.
10. Bonati A, Delia D, Staricich R. Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukemia with unusual phenotype. Br J Haematol 1986; 64: 487-491.
11. Dewald GW, Davis MP, Pierre RV, O'Fallon JR, Hoagland HC. Clinical characteristics and prognosis of 50 patients with a myeloproliferative syndrome and deletion of part of the long arm of chromosome 5. Blood 1985; 66: 189-197.
12. Heim S. Cytogenetic findings in primary and secondary MDS. Leukemia Res 1992; 16: 43-46.
13. Michalova K, Musilova J, Zemanova Z, Czechoslovak MDS Cooperative Group. Consecutive chromosomal studies in patients with myelodysplastic syndrome. Ann Genet 1991; 34: 212-218.
14. Wattel E, Lai JL, Hebbar M, Preudhomme C, Grahek D, Morel P, Bauters F, Fenaux P. De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leukemia Res 1993; 17: 921-926.
15. Estey EH, Kantarjian HM, Keating M. Idarubicin plus continuous infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Semin Oncol 1993; 20: 1-5.
16. Kizaki M, Koeffler HP. Differentiation-inducing agents in the treatment of myelodysplastic syndromes. Semin Oncol 1992; 19: 95-105.
17. Greenberg PL. Treatment of myelodysplastic syndromes with hemopoietic growth factors. Semin Oncol 1992; 19: 106-114.
18. Tefferi A, Thibodeau SN, Solberg LA Jr. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood 1990; 75: 1770-1773.
19. Abrahamson G, Boultwood J, Madden J, Kelly S, Oscier DG, Rack K, Buckle VJ, Wainscoat JS. Clonality of cell populations in refractory anemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses. Br J Haematol 1991; 79: 550-555.
20. Okada M, Okamoto T, Kanamaru A, Kaishita E. Clonal analysis in MDS (refractory anemia) by FISH and X-chromosome inactivation pattern using PCR. Proc Am Soc Hematol 1995; 86: 799a (Abstr. 3183).
21. Delforge M, Duppen VV, Demuynck H, Verhoef GEG, Vandenberghe P, Zachee P, Boogaerts MA. Clonality study of hematopoietic marrow progenitors and mature blood cells in female patients with myelodysplastic syndromes. Proc Am Soc Hematol 1995; 86: 335a (Abstr. 1328).
22. Prchal JT, Throckmorton DW, Carroll III AJ, Fuson EW, Gams RA, Prchal JF. A common progenitor for human myeloid and lymphoid cells. Nature 1978; 274: 590-591.
23. Janssen JWG, Buschle M, Layton M, Drexler HG, Lyons J, van den Berghe H, Heimpel H, Kubanek B, Kleihauer E, Mufti GJ, Bartram CR. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 1989; 73: 248-254.
24. Gale RE, Wheadon H, Goldstone AH, Burnett AK, Linch DC. Frequency of clonal remission in acute myeloid leukaemia. Lancet 1993; 341: 138-142.
25. Claxton D, Deisseroth A, Talpaz M, Reading C, Kantarjian H, Trujillo J, Stass S, Gooch G, Spitzer G. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. Blood 1992; 79: 997-1002.
26. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC, List AF, Taniguchi T. Deletion of IRF-1 mapping to chromosome 5q31.1 in human leukemia and preleukemic myelodysplasia. Science 1993; 259: 968-971.
27. Killman SA. Acute leukemia: the kinetics of leukemic blast cells in man. An analytical review. Semin Hematol 1968; 1: 38-102.
28. Hogge DE. Cytogenetics and oncogenes in leukemia. Curr Opin Oncol 1994; 6: 3-13.
29. Boultwood J, Fidler C, Lewis S, McCarthy A, Sheridan H, Kelly S, Oscier D, Buckle VJ, Wainscoat JS. Allelic loss of IRF-1 in myelodysplasia and acute myeloid leukemia: retention of IRF-1 on the 5q- chromosome in some patients with 5q- syndrome. Blood 1993; 82: 2611-2616.
30. Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N, Lamphier MS, Hirai H, Taniguchi T. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia, leukemia: a possible mechanism of tumor suppressor inactivation. Oncogene 1994; 9: 3313-3320.
31. Harada H, Kitagawa N, Tanaka N, Yamamoto H, Harada K, Ishihara M, Taniguchi T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and 2. Science 1993; 259: 971-974.
32. Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse HC III, Jenkins NA, Copeland NG. Identification of a common ecotropic viral integration site Evi-1 in the DNA of AKXD murine tumors. Mol Cell Biol 1988; 8: 301-308.
33. Morishita K, Parganas E, William CL, Whittaker MH, Drabkin H, Oval J, Taetle R, Valentine MB, Ihle JN. Activation of Evi-1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992; 89: 3937-3941.
34. Jacobs A. Gene mutations in myelodysplasia. Leukemia Res 1992; 16: 47-50.
35. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. Fms mutations in myelodysplastic, leukemic and normal subjects. Proc Natl Acad Sci USA 1990; 87: 1377-1380.
36. Mori N, Hidai H, Yokota J, Okada M, Motoji T, Oshimi K, Mizoguchi H. Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia. Leukemia Res 1995; 19: 869-875.
37. Sheridan BL, Rels MD. Oncogene involvement in myelodysplasia and acute myeloid leukemia. Tumor Biol 1990; 1 (Suppl. 1): 44-58.
38. Raza A, Yousuf N, Bokhari SAJ, Mehdi A, Masterson M, Lampkin B, Yanik G, Mazewski C, Khan S, Preisler HD. Contribution of in vivo proliferation/differentiation studies towards the development of a combined functional and morphologic system of classification of neoplastic disease. Cancer 1992; 69: 1557-1566 (Suppl.).
39. Raza A, Bokahari J, Yousuf N, Mehdi A, Mazewski C, Khan S, Baker V, Lampkin B. Cell cycle kinetic studies in human cancers: development of three DNA-specific labels in three decades. Arch Pathol Lab Med 1991; 115: 873-879.
40. Mundle S, Iftikhar A, Shetty V, Dameron S, Wright-Quinones V, Marcus B, Loew J, Gregory S, Raza A. Novel in situ double-labeling for simultaneous detection of proliferation and apoptosis. J Histochem Cytochem 1994; 42: 1533-1537.
41. Mundle S, Iftikhar A, Shetty V, Alvi S, Dameron S, Gregory S, Marcus B, Khan S, Raza A. In situ end labeling of DNA to detect apoptotic cell death in a variety of human tumors. Cell Death Diff 1994; 1: 117-122.
42. Alvi S, Borok R, Mundle S, Gao X-Z, Shetty V, Hines C, Robin E, Rifkin S, Klein M, Alston D, Hernandez B, Hsu W-T, Gezer S, Gregory S, Raza A. Detection of high molecular weight DNA as evidence of apoptosis in myelodysplasia. Proc Am Soc Hematol 1995; 86: 334 (Abstr. 1324).
43. Raza A, Mundle S, Iftikhar A, Gregory S, Marcus B, Khan Z, Alvi S, Shetty V, Dameron S, Wright V, Adler S, Loew J, Shott S, Ali N, Preisler H. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 1995; 48: 143-154.
44. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharido A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
45. Hibner U, Coutinho A. Signal antonymy: a mechanism for apoptosis induction. Cell Death Diff 1994; 1: 33-37.
46. Verhoef GEG, De Schouwer P, Ceuppens J, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992; 6: 1268-1272.
47. Keller JR, Jacobsen SEW, Dubois CM, Hestdal K, Ruscetti FW. Transforming growth factor-β: a bidirectional regulator of hematopoietic cell growth. Int J Cell Clon 1992; 10: 2-11.
48. Mundle S, Alvi S, Dong L-M, Gezer S, Venugopal P, Hines C, Gregory S, Robin E, Rifkin S, Klein M, Alston D, Hernandez B, Hsu W-T, Shetty V, Raza A. Interleukin-1β converting enzyme-like protease may be involved in the intramedullary apoptotic death in the marrows of patients with myelodysplasia. Proc Am Soc Hematol 1995; 334a (Abstr. 1323).
49. Shetty V, Dar S, Span L, Alvi S, Venugopal P, Gezer S, Borok R, Mundle S, Chopra H, Hines C, Jassak P, Gregory SA, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Raza A. Contribution of macrophages and a variety of cytokines in the pathogenesis of myelodysplastic syndromes (MDS). Proc Am Soc Clin Oncol 1996; 15: 424 Abstr. 1308.
50. Zeigler ZR, Jones D, Rosenfeld CS, Shadduck RK. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. Stem Cells 1993; 11: 49-55.
51. Ganser A, Hoelzer D. Treatment of myelodysplastic syndromes with hematopoietic growth factors. Hematol/Oncol Clin N Am 1992; 6: 633-653.
52. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993; 82: 737-743.
53. Gerhartz HH, Marcus R, Delmer A, Zwierzina H, de Witte T, Jacobs A, Visiani G, Fiere D, Sonneveld P, Labar B, Hoffbrand AV, Fenaux P, Hayat M, Thyss A, Debucher L, Coiffier B, Sizoo W, Willemze R, Ribeiro M, Suciu S, Solbu G, Stern Z, Zittoun R, for the EORTC Leukaemia Group. Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Infection 1992; 20: S116-S123.
54. Bursten S, Weeks R, West J, Le T, Wilson T, Porubek D, Bianco JA, Singer JW, Rice GC. A potential role for phosphatidic acid in mediating the inflammatory responses of TNF-α and IL-1. Circ Shock 1994; 44: 14-29.
55. Abraham E, Burstein S, Shemkar R, Allbee J, Tuder R, Woodson P, Guidot DM, Rice GC, Singer JW, Repine JE. Phosphatidic acid signalling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J Exp Med 1995; 181: 569-575.
56. Clark E, Rice GC, Weeks RS, Jenkins N, Nelson R, Bianco JA, Singer JW. Lisophylline inhibits TGF-β release and enhances trilineage hematopoietic recovery after 5-FU treatment in mice. Cancer Res 1996; 56: 105-112.
57. Ward A, Clossold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1987; 34: 50-97.
58. Thompson JA, Bianco JA, Benyunes MC, Neubauer MA, Slattery JT, Fefer A. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res 1994; 54: 3436-3441.
59. Rice GC, Rosen JW, Weeks R, Michnik J, Bianco JA, Singer JW. CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock 1994; 1: 254-266.